Healio

Ensifentrine improves outcomes in COPD, but unlikely to be cost effective

Please provide your email address to receive an email when new articles are posted on . Ensifentrine plus maintenance therapy yielded multiple benefits in patients with moderate to severe COPD. If ...
Healio

Ensifentrine improves outcomes in both moderate, severe COPD

Please provide your email address to receive an email when new articles are posted on . Patients with moderate or severe COPD experienced improvements with 3 mg of twice-daily ensifentrine. Study ...
The American Journal of Managed Care

Ensifentrine Shows Promise as Add-On, Stand-Alone Therapy in COPD: M. Bradley Drummond, MD, MHS

M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive ...
Medscape

Ensifentrine Offers COPD Patients Relief and Convenience

The recent Food and Drug Administration (FDA) approval of ensifentrine marks the first new treatment for patients with persistent chronic obstructive pulmonary disease (COPD) in more than a decade, ...
Seeking Alpha

Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Their main candidate drug, ensifentrine, has shown promising ...
Monthly Prescribing Reference

Ensifentrine Under Review for Maintenance Treatment of COPD

Credit: Getty Images. Ensifentrine is a first-in-class, dual phosphodiesterase 3 and 4 inhibitor. The Food and Drug Administration has accepted the New Drug Application for ensifentrine for the ...